NORTH CHICAGO, Ill., Nov. 19, 2026 – AbbVie (NYSE: ABBV) today announced a new $217 million investment to modernize its biologics manufacturing campus in Puerto Rico. This modernization will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's current and next-generation immunology and neuroscience medications.
Work will begin this year, with the facility anticipated to be fully operational by 2030. As part of this investment, AbbVie plans to hire 100 people in Puerto Rico, including engineers, scientists, manufacturing operators and lab technicians.
“Our medicines are essential to the patients who rely on them, and our colleagues in Puerto Rico have long been vital to bringing AbbVie’s treatments to patients,” said Azita Saleki, Ph.D., executive vice president and chief operations officer, AbbVie. “This investment reflects our continued commitment to Puerto Rico and to strengthening our U.S. manufacturing network with the advanced technologies, capabilities and skilled workforce needed to ensure a consistent, reliable supply of medicines.”
With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its U.S. manufacturing sites and more than 1,200 in Puerto Rico. The project is part of AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade.
“This $217 million investment by AbbVie sends a strong message about Puerto Rico and our ability to compete for high-value manufacturing operations. AbbVie is a global biopharmaceutical company that not only maintains more than 1,000 jobs on the island, but is also investing in new capacity and creating 100 additional opportunities for our people. Our goal is precisely to ensure that companies already operating here find the conditions they need to reinvest, grow and increase production in Puerto Rico,” said Governor Jenniffer González Colón.
With this announcement, AbbVie has committed to investing more than $2.4 billion in U.S. manufacturing over the past 16 months and creating more than 1,400 jobs in North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico. More information about AbbVie’s U.S. manufacturing investments is available at AbbVie.com/Manufacturing.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, manufacturing difficulties or delays, adverse litigation or government action, changes to laws and regulations applicable to our industry, drug pricing reform and government pricing programs, risks related to the use of artificial intelligence or other emerging technologies, and the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, tariffs and changes in the U.S. and international trade policies, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's most recently filed Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
|
Media: |
Investors: |
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?